Alzheimer’s disease drug-development pipeline: few candidates, frequent failures
Top Cited Papers
Open Access
- 3 July 2014
- journal article
- Published by Springer Nature in Alzheimer's Research & Therapy
- Vol. 6 (4) , 37
Abstract
Introduction: Alzheimer’s disease (AD) is increasing in frequency as the global population ages. Five drugs are approved for treatment of AD, including four cholinesterase inhibitors and an N-methyl-D-aspartate (NMDA)-receptor antagonist. We have an urgent need to find new therapies for AD. Methods: We examined Clinicaltrials.gov, a public website that records ongoing clinical trials. We examined the decade of 2002 to 2012, to better understand AD-drug development. We reviewed trials by sponsor, sites, drug mechanism of action, duration, number of patients required, and rate of success in terms of advancement from one phase to the next. We also reviewed the current AD therapy pipeline. Results: During the 2002 to 2012 observation period, 413 AD trials were performed: 124 Phase 1 trials, 206 Phase 2 trials, and 83 Phase 3 trials. Seventy-eight percent were sponsored by pharmaceutical companies. The United States of America (U.S.) remains the single world region with the greatest number of trials; cumulatively, more non-U.S. than U.S. trials are performed. The largest number of registered trials addressed symptomatic agents aimed at improving cognition (36.6%), followed by trials of disease-modifying small molecules (35.1%) and trials of disease-modifying immunotherapies (18%). The mean length of trials increases from Phase 2 to Phase 3, and the number of participants in trials increases between Phase 2 and Phase 3. Trials of disease-modifying agents are larger and longer than those for symptomatic agents. A very high attrition rate was found, with an overall success rate during the 2002 to 2012 period of 0.4% (99.6% failure). Conclusions: The Clinicaltrials.gov database demonstrates that relatively few clinical trials are undertaken for AD therapeutics, considering the magnitude of the problem. The success rate for advancing from one phase to another is low, and the number of compounds progressing to regulatory review is among the lowest found in any therapeutic area. The AD drug-development ecosystem requires support.Keywords
This publication has 26 references indexed in Scilit:
- Moving towards early clinical trials for amyloid-targeted therapy in Alzheimer's diseaseNature Reviews Drug Discovery, 2013
- Evolution of the evidence on the effectiveness and cost-effectiveness of acetylcholinesterase inhibitors and memantine for Alzheimer's disease: systematic review and economic model†Age and Ageing, 2012
- Advances in the pathogenesis of Alzheimer’s disease: a re-evaluation of amyloid cascade hypothesisTranslational Neurodegeneration, 2012
- Increasing the success rate for Alzheimer's disease drug discovery and developmentExpert Opinion on Drug Discovery, 2012
- The Database for Aggregate Analysis of ClinicalTrials.gov (AACT) and Subsequent Regrouping by Clinical SpecialtyPLOS ONE, 2012
- Donepezil and Memantine for Moderate-to-Severe Alzheimer's DiseaseNew England Journal of Medicine, 2012
- Report of the task force on designing clinical trials in early (predementia) ADNeurology, 2011
- Globalization of Alzheimer's disease clinical trialsAlzheimer's Research & Therapy, 2011
- Modeling an Anti-Amyloid Combination Therapy for Alzheimer’s DiseaseScience Translational Medicine, 2010
- Of Mice and MenCNS Drugs, 2009